SAN DIEGO--(BUSINESS WIRE)-- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Jill Howe as Chief Financial Officer. Ms. Howe brings proven capabilities in private and public financial management, and will oversee all aspects of DTx’s finances.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005217/en/

Jill Howe (Photo: Business Wire)

“We are pleased to welcome Jill Howe to the role of CFO,” said Arthur T. Suckow, Co-Founder and Chief Executive Officer of DTx Pharma. “Jill played a key role in the success of several San Diego-based biotechnology companies over the past several years. We look forward to leveraging her expertise in finance and corporate strategy as we create medicines for patients with significant unmet need and drive value for our shareholders.”

Ms. Howe brings to the role more than 20 years of finance experience in the biotechnology sector, including a track record of success in operational and financial strategy, as well as treasury, global infrastructure, and compliance management. Prior to joining DTx, Ms. Howe served as Treasurer and Vice President of Finance for Gossamer Bio, a clinical-stage biopharmaceutical company, where she was the internal project lead for the company’s initial public offering, follow-on, and debt offerings. In addition to building a successful finance team at Gossamer Bio, she oversaw finance for 18 subsidiaries across the U.S. and Ireland. Previously, Ms. Howe held Controller and Director of Finance roles at Amplyx Pharmaceuticals, Receptos, and Somaxon Pharmaceuticals.

Ms. Howe holds a Bachelor of Arts in Accounting from San Diego State University and is a graduate of the Women in Bio Board Room Ready program.

“I am excited to join DTx at this pivotal time in the company’s history and look forward to working closely with the management team to achieve the next phase of the company’s growth objectives,” said Ms. Howe. “This opportunity is appealing because of the world-class talent the team has attracted, the novel FALCON technology on which DTx has made impressive progress to date, and the continual focus on finding solutions for patients with unmet medical needs.”

About DTx Pharma

DTx Pharma, Inc. is a privately-held biotechnology company based in San Diego, CA creating novel RNA-based therapeutics to treat the genetic drivers of disease. The company’s proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types. To advance the FALCON platform toward and into clinical development, DTx has raised more than $100M in combined investment from several of the world’s leading healthcare investors including RA Capital Management and Access Biotechnology, pharmaceutical companies such as Eli Lilly and Company, the National Institute of Health (NIH), and research foundations such as the CMT Research Foundation (CMTRF). To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on LinkedIn and Twitter @DTxPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005217/en/